Earlier-Line and New-Indication Label Expansion — Labels are moving up the treatment sequence, and revenue is following. Bristol Myers Squibb's Breyanzi grew 82% to USD 1,358 Mn in 2025, with international sales up 132%, after approvals stretched from second-line large B-cell lymphoma into follicular, mantle cell and chronic lymphocytic leukemia indications. The FDA then approved Breyanzi in marginal zone lymphoma in December 2025, the first CAR-T cleared for that disease. In myeloma, Carvykti's second-line label is doing the same work; Legend Biotech reported Q2 2026 net trade sales of about USD 657 Mn, up 50% year on year. Each new line of therapy adds a patient pool that is fitter, easier to manufacture for and more likely to complete treatment. North America and Europe capture most of this effect today, with Carvykti's ex-U.S. sales up 128% in Q2 2026.
CAR-T Cell Therapy Market Report 2026–2035: Size, Share & Trends
CAR-T Cell Therapy Market by Product Type (Autologous CAR-T, Allogeneic CAR-T, In-Vivo CAR-T), by Target Antigen (CD19-Targeted, BCMA-Targeted, CD22-Targeted, Others), by Application (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Solid Tumors, Others), by End User (Hospitals & Cancer Centers, Specialty Treatment Centers, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
CAR-T Cell Therapy Industry Perspective
The Global CAR-T Cell Therapy market stood at USD 4,372.8 Mn in 2025 and is projected to reach USD 23,915.3 Mn by 2035, growing at a CAGR of 18.52% during the forecast period 2026–2035, according to Vectomat Insights.
CD19-targeted therapies account for half of base-year revenue, yet the market's center of gravity is shifting toward BCMA products in multiple myeloma and toward allogeneic and in-vivo platforms that remove the vein-to-vein wait from treatment.
CAR-T Cell Therapy Market: Overview
CAR-T Cell Therapy Market encompasses genetically modified T-cell products that carry a chimeric antigen receptor directed at a cell-surface antigen such as CD19, BCMA, CD22 or Claudin18.2. The report scope covers autologous products made from each patient's own cells, allogeneic products made from healthy donors, and in-vivo approaches that program T cells inside the body with a viral vector or lipid nanoparticle. Revenue is measured at the manufacturer level across hematologic cancers, solid tumors and early autoimmune use.
The value chain runs in three tiers. Foundational providers such as Miltenyi Biomedicine supply the cell-processing platforms and vectors that every manufacturing run depends on, alongside decentralized producers such as India's ImmunoACT. Specialist developers, including Allogene Therapeutics, Caribou Biosciences, CARsgen Therapeutics, AbbVie and AstraZeneca, are building the next generation of off-the-shelf, in-vivo and solid-tumor programs. Application-layer specialists, led by Gilead Sciences, Bristol Myers Squibb and Johnson & Johnson, run the commercial supply chains that deliver approved products to accredited treatment centers.
For procurement and investment decision-makers, the live question isn't whether CAR-T grows; it's which antigens, manufacturing models and geographies take the largest slice of that growth. This report gives sub-segment revenue, country-level forecasts and competitive positioning across four segmentation dimensions and 35+ countries, so buyers can test their own base case against an independent view.
According to Federal Joint Committee (G-BA), Germany — AMNOG resolution on ciltacabtagene autoleucel, 2025-05-15, The G-BA estimated 2,360 to 3,550 statutory health insurance patients in Germany fall within the target population for cilta-cel in relapsed and refractory multiple myeloma after one to three prior lines, a single-country, single-indication pool that shows how far eligible demand still runs ahead of current treatment capacity.
Key Insights
- The market expands from USD 4,372.8 Mn in 2025 to USD 23,915.3 Mn by 2035, an 18.52% CAGR across the 2026–2035 forecast horizon.
- Autologous CAR-T dominates product type with 68.0% of 2025 revenue (USD 2,973.5 Mn), the format behind all seven FDA-approved CAR-T therapies.
- Allogeneic CAR-T is the fastest-growing product type by a narrow margin, rising from USD 684.8 Mn in 2023 to USD 962.0 Mn in 2025 (an 18.5% two-year CAGR); Allogene's cema-cel passed its ALPHA3 futility analysis in April 2026.
- Non-Hodgkin Lymphoma is the dominant application at 36.0% share (USD 1,574.2 Mn), because large B-cell lymphoma carries the broadest set of CD19 labels across Yescarta, Breyanzi and Kymriah.
- Hospitals & Cancer Centers lead end users with 66.0% share (USD 2,886.0 Mn), since FACT-accredited inpatient capacity still governs where patients are infused; roughly 250 accredited U.S. centers existed by mid-2026.
- North America holds 45.0% of 2025 revenue (USD 1,967.8 Mn), and the United States alone is worth USD 1,574.2 Mn.
- Asia Pacific is the fastest-growing region; South Korea is forecast to grow at 20.7% CAGR and Japan at 18.8% through 2035, both ahead of the U.S. at 17.3%.
- Competition is consolidating around BCMA and in-vivo assets: Gilead closed its USD 7.8 Bn Arcellx acquisition in April 2026, ahead of an FDA decision on anito-cel due 23 December 2026.
- China's June 2026 approval of CARsgen's satri-cel, the first CAR-T cleared for a solid tumor, opens a demand pool that already accounts for 10.0% of 2025 revenue in this report's segmentation.
CAR-T Cell Therapy Market: Report Scope
| Report Name | CAR-T Cell Therapy Market by Product Type (Autologous CAR-T, Allogeneic CAR-T, In-Vivo CAR-T), by Target Antigen (CD19-Targeted, BCMA-Targeted, CD22-Targeted, Others), by Application (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Solid Tumors, Others), by End User (Hospitals & Cancer Centers, Specialty Treatment Centers, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035 |
|---|---|
| Market Size in 2025 | USD 4,372.8 Mn (2025) |
| Market Forecast in 2035 | USD 23,915.3 Mn (2035) |
| Growth Rate (CAGR) | 18.52% |
| Historical Data Period | 2023–2025 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| Number of Pages | 300+ |
| Tables & Figures | 96 tables & 72 figures |
| Report Code | VMI-1-5-20666 |
| Report Format | |
| Delivery Format | PDF via email delivery and online download portal |
| Published Date | October 2026 |
| Research Methodology | Primary + Secondary |
| Key Companies Covered | Gilead Sciences, Novartis, Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Autolus Therapeutics, JW Therapeutics, CARsgen Therapeutics, IASO Biotherapeutics, Allogene Therapeutics, Caribou Biosciences, AbbVie, AstraZeneca, ImmunoACT, Miltenyi Biomedicine |
| Segments Covered | Product Type, Target Antigen, Application, End User |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, The Middle East, Africa |
| Customization Scope | Up to 10% free customization: additional country breakdowns, company profiles, or segment cuts (e.g. by line of therapy or manufacturing model) on request |
Why Choose the VMI CAR-T Cell Therapy Market Report?
Decision-makers comparing market intelligence reports on CAR-T Cell Therapy will find the VMI report differentiated on the following dimensions.
| Dimension | VMI Report | Industry Average |
|---|---|---|
| Report Pages | 300+ | ~120 pages |
| Forecast Horizon | 10 years | 7 years |
| Segmentation Dims | 4 dims | 4-5 dimensions |
| Historical Data | 3 years | 4-5 years |
| Country Coverage | 35+ countries | 15-18 countries |
| Companies Profiled | 15 companies | 10-12 companies |
| DROC Framework | Full (4 elem) | Drivers only |
For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com
What Is Driving the CAR-T Cell Therapy Market?
Regulatory Easing and Outpatient Delivery — Regulators have removed one of the biggest logistical barriers. In June 2025 the FDA eliminated the REMS programs for Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta, shortening the required stay near the treatment facility and the driving restriction to two weeks each and dropping on-site tocilizumab certification. Delivery models were already shifting: the hospital outpatient share of U.S. CAR-T administrations rose from 17% in 2022 to 35% in 2025, according to a Prime Therapeutics claims analysis. Vanderbilt's Olalekan Oluwole has reported community-center outcomes comparable to academic sites, which strengthens the case for wider networks. A shorter stay matters most to patients who live hours from one of the roughly 250 accredited U.S. centers. Cencora's June 2026 agreement to support Yescarta and Tecartus distribution to community oncology practices is the commercial follow-through.
Big-Pharma Investment in Next-Generation Platforms — Capital is flowing in at a scale the category hasn't seen before. AstraZeneca agreed to buy EsoBiotec for up to USD 1.0 Bn in March 2025, AbbVie agreed to acquire Capstan Therapeutics for up to USD 2.1 Bn in June 2025, and Kite bought Interius BioTherapeutics for USD 350 Mn in August 2025, all for in-vivo programs that skip ex vivo manufacturing. Gilead then paid about USD 7.8 Bn for Arcellx, a 79% premium, to secure the BCMA therapy anito-cel ahead of a December 2026 FDA decision. These buyers bring global commercial reach, manufacturing capital and payer relationships that single-asset biotechs lack. Structurally, it means the next decade of CAR-T growth will be financed and launched by diversified pharma groups rather than by venture-backed developers alone.
Anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy.
(Source: Gilead Sciences announcement of the Arcellx acquisition (via Financier Worldwide), 2026-02-23)
What Is Restraining the CAR-T Cell Therapy Market?
High Treatment Cost and Reimbursement Gaps — Price is still the hardest ceiling on volume. U.S. wholesale acquisition costs for the six established products ranged from USD 462,000 for Tecartus to USD 593,533 for Kymriah in 2025, having climbed 3-7% a year since 2022, according to Stanford's Health Management and Policy Institute. Hospital economics add a second layer: CMS denied a new-technology add-on payment to Aucatzyl for fiscal 2026, judging it substantially similar to Tecartus, and outpatient reimbursement runs roughly 14-17% below inpatient payment. Outside the wealthiest systems, the gap is wider still; Brazil's public SUS program is building its own CAR-T because imported product is unaffordable. The result is a treatment rate near 20% of eligible U.S. patients, as reported by Cell and Gene Therapy Insights in October 2026.
Manufacturing Lead Times and Treatment-Center Access — Autologous CAR-T is a logistics product as much as a drug. Even after Kite cut Yescarta's median U.S. turnaround from 16 to 14 days, patients with aggressive disease must wait through collection, manufacturing and release, and some progress before infusion. Access is uneven: a University of California study of more than 12,000 myeloma patients found only 2.6% received CAR-T between 2012 and 2025, with Black patients significantly less likely to be treated. Community oncologist Jeff Sharman has described CAR-T as historically out of reach for community practices. Allogene Therapeutics is testing the alternative directly, with about one-third of ALPHA3 trial sites in community cancer centers.
Historically, CAR T has largely been out of reach for community practices.
(Source: Targeted Oncology, 2026-04)
What Opportunities Exist in the CAR-T Cell Therapy Market?
Autoimmune Disease Indications — Autoimmune disease is the largest new demand pool on the horizon. Kyverna Therapeutics reported positive registrational data for miv-cel in stiff person syndrome in January 2026, and Novartis presented rap-cel results in lupus, systemic sclerosis and myositis at EULAR in June 2026. AbbVie's Capstan deal targets the same space with an in-vivo approach that avoids chemotherapy conditioning. A single course of therapy that resets the immune system would compete with years of chronic biologic spending. Lupus and other B-cell-driven autoimmune diseases affect far larger patient populations than today's CAR-T-eligible lymphoma cohorts.
Solid-Tumor CAR-T — Solid tumors make up the vast majority of cancer deaths, and CAR-T has finally crossed into them. China's NMPA approved CARsgen Therapeutics' Claudin18.2-targeted satri-cel in June 2026 for patients with advanced gastric or gastroesophageal junction cancer after two or more prior lines. In its pivotal trial, satri-cel extended median progression-free survival to 3.25 months versus 1.77 months with physician's-choice chemotherapy. The benefit is modest, but the precedent matters for every developer working on solid-tumor antigens. CARsgen has priced the therapy at about RMB 0.99 Mn.
Low-Cost and Regional Manufacturing Models — Lower-cost production can open markets that Western pricing never will. India's ImmunoACT sells NexCAR19 for roughly USD 31,000-37,000 and has treated more than 500 patients, and in January 2026 it licensed the therapy to Cipla for South Africa, Algeria and Morocco. In Riyadh, King Faisal Specialist Hospital & Research Centre began treating patients with locally manufactured CAR-T in October 2025. Point-of-care platforms such as Miltenyi Biomedicine's CliniMACS Prodigy make this model practical. In structural terms, CAR-T is becoming a manufacturing capability that health systems can build, not only a product they must import.
What Challenges Does the CAR-T Cell Therapy Market Face?
Competitive Erosion of First-Wave CD19 Products — First-mover advantage is fading in CD19. Novartis' Kymriah fell 14% to USD 381 Mn in 2025, Gilead's Yescarta slipped 5% to USD 1,495 Mn and Tecartus dropped 15%, while Breyanzi grew 82%. Bispecific antibodies add out-of-class pressure in lymphoma and myeloma. In Q2 2026, Gilead's total cell-therapy revenue was down 14% year on year at USD 417 Mn.
Long-Term Safety Monitoring — Removing REMS did not remove the safety conversation. The FDA kept boxed warnings on approved CAR-T products, including the class warning on secondary T-cell malignancies, so sponsors still owe long-term follow-up data. Cytokine release syndrome and neurotoxicity also require monitored infusion sites. Autolus Therapeutics built its commercial case for Aucatzyl around lower rates of severe toxicity in adult ALL.
Commercial CAR-T products are economically unfeasible for Brazil's public health system, which is why the goal is a completely national technology that SUS patients can access. (paraphrased)
(Source: Jornal da USP, 2025-01)
The Role of AI in the CAR-T Cell Therapy Market
Point-of-care manufacturing is where AI is entering CAR-T first. The EU-funded AIDPATH project installed its first automated manufacturing module at University Hospital Würzburg in 2025, using AI-driven digital twins and real-time monitoring of culture parameters to adjust each production run to the individual patient's clinical data. The aim is to make decentralized manufacturing consistent enough to run inside a hospital rather than a central plant.
For hospitals, that shifts CAR-T from a shipped product toward a locally controlled process, with scheduling, release testing and patient data linked in one system. Central plants set the bar any AI-controlled process has to clear: Kite reports a 96% manufacturing success rate and JW Therapeutics 98%. Expect AI-based process control to become a selling point for platform vendors as more academic centers build in-house capacity through 2035.
CAR-T Cell Therapy Market: Segmentation
The Global CAR-T Cell Therapy market is segmented by Product Type, Target Antigen, Application, End User.
By Product Type
Autologous CAR-T dominates with 68.0% of 2025 revenue, or USD 2,973.5 Mn. Its lead rests on regulatory precedent: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti and Aucatzyl are all made from the patient's own cells, and Johnson & Johnson and Legend Biotech's Carvykti alone generated about USD 1.9 Bn of net trade sales in 2025. Allogeneic CAR-T, at 22.0% share (USD 962.0 Mn), is the fastest-growing type by a hair, rising from USD 684.8 Mn in 2023; historical growth was near-uniform at about 18.5% across all three types, so the forecast spread will be set by clinical readouts rather than by the base period. Caribou Biosciences aligned with the FDA on a 250-patient Phase 3 trial of vispa-cel in August 2026. In-Vivo CAR-T holds 10.0% (USD 437.3 Mn) and is where the next decade's manufacturing economics will be decided.
CAR-T Cell Therapy Market Size, By Product Type, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Autologous CAR-T | 2,116.8 | 2,508.9 | 2,973.5 |
| Allogeneic CAR-T | 684.8 | 811.7 | 962.0 |
| In-Vivo CAR-T | 311.3 | 369.0 | 437.3 |
By Target Antigen
CD19-targeted therapies hold half of 2025 revenue, 50.0% or USD 2,186.4 Mn, because CD19 was the first validated CAR-T target and still anchors five of the seven U.S. approvals across lymphoma and leukemia. BCMA-targeted products follow at 28.0% (USD 1,224.4 Mn), with Carvykti and Abecma in myeloma. The 'Others' category, at 12.0% (USD 524.7 Mn), edged out every other antigen on 2023–2025 growth at 18.5%; it now includes Claudin18.2, after China's NMPA approved CARsgen Therapeutics' satri-cel for gastric cancer in June 2026, plus CD20 and dual-target constructs. CD22-targeted therapies take 10.0% (USD 437.3 Mn), largely as a rescue option for CD19-negative relapse. Expect BCMA's share to climb once Gilead brings anito-cel to market after its 23 December 2026 FDA decision.
CAR-T Cell Therapy Market Size, By Target Antigen, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| CD19-Targeted | 1,556.5 | 1,844.8 | 2,186.4 |
| BCMA-Targeted | 871.6 | 1,033.1 | 1,224.4 |
| CD22-Targeted | 311.3 | 369.0 | 437.3 |
| Others | 373.5 | 442.7 | 524.7 |
By Application
Non-Hodgkin Lymphoma is the largest application at 36.0% of 2025 revenue (USD 1,574.2 Mn), driven by second-line large B-cell lymphoma labels for Yescarta and Breyanzi and by Breyanzi's December 2025 FDA approval in marginal zone lymphoma. Acute Lymphoblastic Leukemia follows with 24.0% (USD 1,049.5 Mn) and Multiple Myeloma with 22.0% (USD 962.0 Mn). Growth across applications was near-identical between 2023 and 2025, with 'Others', a category that captures early autoimmune use and rarer B-cell cancers, edging ahead at 18.5%. Solid Tumors already account for 10.0% (USD 437.3 Mn) of this report's base year. Autolus Therapeutics booked USD 74.3 Mn of Aucatzyl sales in 2025, its first full launch year in adult ALL. Myeloma is the application to watch, because BCMA therapies are moving into earlier lines.
CAR-T Cell Therapy Market Size, By Application, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Non-Hodgkin Lymphoma | 1,120.7 | 1,328.2 | 1,574.2 |
| Acute Lymphoblastic Leukemia | 747.1 | 885.5 | 1,049.5 |
| Multiple Myeloma | 684.8 | 811.7 | 962.0 |
| Solid Tumors | 311.3 | 369.0 | 437.3 |
| Others | 249.0 | 295.1 | 349.8 |
By End User
Hospitals & Cancer Centers account for 66.0% of 2025 revenue (USD 2,886.0 Mn). That's a function of accreditation: CAR-T has to be infused at a certified site with intensive-care backup, and the U.S. counted just over 250 FACT-accredited centers by mid-2026. Specialty Treatment Centers hold 22.0% (USD 962.0 Mn), a share that's widening as outpatient infusions rose from 17% of U.S. administrations in 2022 to 35% in 2025. Academic & Research Institutes, at 12.0% (USD 524.7 Mn), were marginally the fastest-growing end user between 2023 and 2025 at 18.5%, helped by point-of-care manufacturing at sites such as King Faisal Specialist Hospital in Riyadh. Distribution deals, including Cencora's June 2026 agreement to support Yescarta and Tecartus delivery to community practices, will pull more volume out of the large centers.
CAR-T Cell Therapy Market Size, By End User, 2023–2025 (USD Million)
| Sub-Segment | 2023 (USD Mn) | 2024 (USD Mn) | 2025 (USD Mn) |
|---|---|---|---|
| Hospitals & Cancer Centers | 2,054.5 | 2,435.0 | 2,886.0 |
| Specialty Treatment Centers | 684.8 | 811.7 | 962.0 |
| Academic & Research Institutes | 373.5 | 442.7 | 524.7 |
CAR-T Cell Therapy Market: Production & Volume Analysis, 2025
Volume here is counted as patients treated, one infusion per patient. Vectomat Insights estimates about 16,800 patients received a CAR-T product in 2025, which implies an average realized price near USD 260,000 against USD 4,372.8 Mn of revenue. Autologous CAR-T leads volume with 60.0% of patients but 68.0% of value, because its U.S. list prices of roughly USD 462,000-594,000 sit well above off-the-shelf formats. That volume-value split favors allogeneic (26.0% of patients) and in-vivo (14.0%) programs.
| Metric | 2025 Volume (patients treated (infusions)) | Share of Units |
|---|---|---|
| Total patients treated (infusions) (2025) | 16,800 | 100.0% |
| Autologous CAR-T | 10,080 | 60.0% |
| Allogeneic CAR-T | 4,368 | 26.0% |
| In-Vivo CAR-T | 2,352 | 14.0% |
Reference point: Legend Biotech / Johnson & Johnson — Reported more than 10,000 cumulative clinical and commercial patients treated with Carvykti and completed a Raritan, NJ plant expansion with capacity for up to 10,000 patients a year (March 2026). More than 10,000 cumulative patients treated.
CAR-T Cell Therapy Market: Competitive Landscape
Seven autologous products earn nearly all commercial revenue today, and four companies, Johnson & Johnson with Legend Biotech, Gilead Sciences and Bristol Myers Squibb, hold the bulk of it. The order is shifting. Carvykti's Q2 2026 sales rose about 50% while Gilead's cell-therapy revenue fell 14%, and Novartis' Kymriah dropped 14% in 2025. A second tier of specialist developers is attacking cost and access from different angles: allogeneic programs at Allogene Therapeutics and Caribou Biosciences, in-vivo platforms at AbbVie, AstraZeneca and IASO Biotherapeutics, and solid tumors at CARsgen Therapeutics. Regional champions such as JW Therapeutics and ImmunoACT price far below U.S. levels, while Autolus Therapeutics and Miltenyi Biomedicine compete on safety and decentralized manufacturing. Key players include Gilead Sciences, Novartis, Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Autolus Therapeutics, JW Therapeutics, CARsgen Therapeutics, IASO Biotherapeutics, Allogene Therapeutics, Caribou Biosciences, AbbVie, AstraZeneca, ImmunoACT, and Miltenyi Biomedicine, among others.
| Company | HQ Country | Primary Focus | Key Strategy | Notable Recent Action |
|---|---|---|---|---|
| Gilead Sciences | U.S. | CD19 CAR-T via Kite (Yescarta, Tecartus); BCMA via anito-cel | Defend CD19 franchise while buying BCMA and in-vivo platforms | Completed USD 7.8 Bn acquisition of Arcellx in April 2026; FDA decision on anito-cel due December 2026 |
| Novartis | Switzerland | Kymriah (CD19) and rapidly manufactured rap-cel for autoimmune disease | Pivot CAR-T toward immunology as oncology sales decline | Presented rap-cel data in lupus, systemic sclerosis and myositis at EULAR in June 2026 |
| Bristol Myers Squibb | U.S. | Breyanzi (CD19) and Abecma (BCMA) | Broadest CD19 label across B-cell cancers plus automated manufacturing capacity | Won FDA approval of Breyanzi in marginal zone lymphoma in December 2025 |
| Johnson & Johnson | U.S. | Carvykti (BCMA) co-commercialized with Legend Biotech | Move BCMA CAR-T into earlier myeloma lines and scale ex-U.S. sites | Carvykti reached 348 treatment sites in 19 markets by August 2026 |
| Legend Biotech | U.S. | Carvykti (cilta-cel) manufacturing and commercialization partner | Capacity expansion to support earlier-line myeloma demand | Passed 10,000 cumulative patients treated and completed Raritan plant expansion in March 2026 |
| Autolus Therapeutics | U.K. | Aucatzyl (obe-cel), CD19 CAR-T for adult B-ALL | Lead adult ALL on safety, then expand into autoimmune disease | Launched Aucatzyl under routine NHS commissioning after a NICE recommendation in January 2026 |
| JW Therapeutics | China | Carteyva (relma-cel), CD19 CAR-T in China | Expand domestic access through commercial insurance coverage | Carteyva added to China's first national commercial health insurance drug catalog in December 2025 |
| CARsgen Therapeutics | China | Satri-cel (Claudin18.2) and zevor-cel (BCMA) | First mover in solid-tumor CAR-T | Won NMPA approval of satri-cel, the first solid-tumor CAR-T, in June 2026 |
| IASO Biotherapeutics | China | Fucaso (eque-cel, BCMA) and in-vivo CAR-T | Regional export of eque-cel plus an in-vivo pipeline | Received FDA IND clearance for an in-vivo CD20 CAR-T in September 2026 |
| Allogene Therapeutics | U.S. | Allogeneic CD19 CAR-T cema-cel | Off-the-shelf first-line consolidation delivered at community sites | ALPHA3 trial of cema-cel passed its interim futility analysis in April 2026 |
| Caribou Biosciences | U.S. | CRISPR-edited allogeneic CAR-T (vispa-cel, CB-011) | Allogeneic therapy for patients unable to access autologous products | Aligned with the FDA on the ANTLER-3 Phase 3 trial of vispa-cel in August 2026 |
| AbbVie | U.S. | In-vivo CD19 CAR-T (CPTX2309) for autoimmune disease | Build an in-vivo immunology franchise without ex vivo manufacturing | Agreed to acquire Capstan Therapeutics for up to USD 2.1 Bn in June 2025 |
| AstraZeneca | U.K. | In-vivo lentiviral ENaBL platform via EsoBiotec | In-vivo cell therapy across oncology and immunology | Agreed to acquire EsoBiotec for up to USD 1.0 Bn in March 2025 |
| ImmunoACT | India | NexCAR19 (talicabtagene autoleucel), low-cost CD19 CAR-T | Ultra-low-cost CAR-T for India and emerging markets | Licensed talicabtagene autoleucel to Cipla for South Africa, Algeria and Morocco in January 2026 |
| Miltenyi Biomedicine | Germany | CliniMACS Prodigy point-of-care manufacturing and zamto-cel (CD20/CD19) | Decentralized manufacturing plus its own tandem-target product | Presented DALY 2-EU pivotal crossover data for zamto-cel at EHA in June 2026 |
Strategic activity clusters around three themes. First, platform M&A: AbbVie, AstraZeneca and Kite bought in-vivo developers in 2025, and Gilead added Arcellx in 2026. Second, earlier-line label expansion, as Breyanzi and Carvykti move up the treatment sequence. Third, capacity and distribution, from Legend's 10,000-patient Raritan plant to Cencora's community-oncology delivery agreement. Expect pricing pressure on CD19 incumbents to intensify as off-the-shelf options reach pivotal data.
CAR-T Cell Therapy Market: Supply Chain Analysis
Cell collection and vector supply — Every autologous therapy starts with leukapheresis at an accredited center, followed by shipment of the patient's cells under chain-of-identity controls. Viral vectors, cell-selection reagents and closed processing systems form the input layer; Miltenyi Biomedicine's CliniMACS Prodigy is the most common platform for decentralized processing. Vector supply and apheresis slot availability are the two capacity points that most often set the start date for treatment. Key Players: Miltenyi Biomedicine.
Manufacturing and release — Engineered cells are expanded, tested and cryopreserved at central plants, a process Kite has cut to a median 14-day U.S. turnaround for Yescarta. Manufacturing success rates now run at 96-98% for leading sponsors, but capacity still caps volume: Legend Biotech's expanded Raritan site can supply up to 10,000 patients a year. Allogeneic and in-vivo models aim to remove this step from the patient's critical path entirely. Key Players: Legend Biotech.
Distribution and administration — Finished doses ship frozen to accredited hospitals and cancer centers, where patients receive lymphodepletion, infusion and monitoring for cytokine release syndrome and neurotoxicity. The June 2025 REMS removal and a shift to outpatient infusion, 35% of U.S. administrations in 2025, are pushing delivery toward community practices. Distributors are adapting: Cencora agreed in June 2026 to support Yescarta and Tecartus delivery to a wider site network. Key Players: Cencora.
CAR-T Cell Therapy Market: Regional Analysis
North America leads the CAR-T Cell Therapy market with 45.0% of 2025 revenue, while Asia Pacific grows fastest. The split comes down to infrastructure versus momentum: the U.S. already has seven approved products and about 250 accredited centers, whereas China, Japan and South Korea are adding domestic approvals and reimbursement from a much smaller base.
North America CAR-T Cell Therapy Market
North America accounts for 45.0% of global CAR-T revenue, worth USD 1,967.8 Mn in 2025. The United States carries almost all of it at USD 1,574.2 Mn, growing at a 17.3% CAGR to USD 7,763.2 Mn by 2035. Seven FDA-approved products, a June 2025 decision to drop REMS requirements, and a network of just over 250 accredited centers give the U.S. a delivery base no other country matches. Price is the friction: list prices run from about USD 462,000 to USD 594,000, and only around 20% of eligible U.S. patients currently receive CAR-T. Canada adds smaller volumes through provincial programs. Bristol Myers Squibb's Breyanzi posted USD 994 Mn of U.S. sales in 2025, up 68%.
United States CAR-T Cell Therapy Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 1,574.2 Mn |
| Forecast Value (2035) | USD 7,763.2 Mn |
| CAGR (2026–2035) | 17.3% |
Europe CAR-T Cell Therapy Market
Germany's CAR-T market reached USD 354.2 Mn in 2025 and is forecast to grow at 16.9% a year to USD 1,688.1 Mn by 2035. Europe as a whole holds 27.0% of global revenue (USD 1,180.7 Mn). Health technology assessment sets the pace here: Germany's G-BA found a hint of considerable added benefit for Carvykti in one to three prior lines in May 2025, while England's NICE backed routine NHS use of Aucatzyl from January 2026. Spain stands out for Hospital Clínic Barcelona's academic CAR-T, ARI-0001, produced under hospital exemption. Country-by-country reimbursement remains the main brake on uptake. The European Commission's November 2025 approval of Breyanzi in mantle cell lymphoma shows labels are widening faster than budgets.
Germany CAR-T Cell Therapy Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 354.2 Mn |
| Forecast Value (2035) | USD 1,688.1 Mn |
| CAGR (2026–2035) | 16.9% |
Asia Pacific CAR-T Cell Therapy Market
South Korea is the fastest-growing country tracked in this report, with a USD 149.5 Mn market in 2025 set to expand at 20.7% a year to USD 981.1 Mn by 2035. Asia Pacific holds 19.0% of global revenue (USD 830.8 Mn) and grows faster than any other region. Japan is the larger market at USD 224.3 Mn, growing at 18.8%, with five approved CAR-Ts reimbursed near ¥32.6 Mn per patient. China has nine NMPA-approved products priced between RMB 0.99 Mn and RMB 1.29 Mn, yet none sits on the basic national reimbursement list. Affordability outside Japan and Korea is the binding constraint. Domestic developers set the pace: Curocell's Rimqarto became Korea's first locally developed CAR-T in April 2026.
South Korea CAR-T Cell Therapy Market Snapshot
| Metric | Value |
|---|---|
| Market Size (2025) | USD 149.5 Mn |
| Forecast Value (2035) | USD 981.1 Mn |
| CAGR (2026–2035) | 20.7% |
Latin America CAR-T Cell Therapy Market
Latin America represents 4.0% of the global market, or USD 174.9 Mn, in 2025, with Brazil the clear lead country. Access runs largely through public research rather than commercial launches. The Brazilian Ministry of Health funds the Carthedrall program, in which the Ribeirão Preto Blood Center, the University of São Paulo and the Butantan Institute make CAR-T cells at the Nutera facility; ANVISA cleared it to enter Phase 2 in December 2024, with 81 patients planned across five centers. The cost of imported therapy is the main barrier, since list prices exceed what the public SUS system can fund. A home-grown manufacturing base is what makes CAR-T viable in this region, not imported product.
The Middle East CAR-T Cell Therapy Market
The Middle East accounts for 3.0% of global CAR-T revenue, worth USD 131.2 Mn in 2025. Saudi Arabia and the UAE lead within the GCC, and Israel adds academic depth through Sheba Medical Center's point-of-care manufacturing. King Faisal Specialist Hospital & Research Centre in Riyadh had treated more than 200 CAR-T patients by October 2025 and started dosing patients with locally made cells. A thin specialist workforce and the need to import most commercial products limit how fast centers can scale. Regional growth tracks state investment in hospital capacity, so volumes should rise steadily as Gulf health systems add accredited cell-therapy units through 2035, at 3.0% share in the base year.
Africa CAR-T Cell Therapy Market
Africa holds a 2.0% share of the global market, or USD 87.5 Mn, in 2025, with South Africa and Egypt the most active countries. Commercial availability is thin and treatment largely requires referral to centers abroad. Infrastructure is the main restraint: few hospitals have the apheresis, cell-processing and intensive-care capacity CAR-T demands. Licensing may change that faster than local build-out. In January 2026, Cipla, through Medpro Pharmaceutica, took an exclusive license to commercialize ImmunoACT's talicabtagene autoleucel, a lower-cost CD19 CAR-T, in South Africa, Algeria and Morocco.
Full Country Coverage
| Region | Countries Covered |
|---|---|
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com
Public Sector Involvement in the CAR-T Cell Therapy Market
Regulatory-approval program — The FDA eliminated the REMS requirements for all six autologous CD19 and BCMA CAR-T therapies in June 2025, shortening the required stay near a treatment center to two weeks and removing on-site tocilizumab certification. (FDA Risk Evaluation and Mitigation Strategies (REMS) elimination for autologous CAR-T)
Reimbursement/funding initiative — Health technology assessment bodies now decide access in Europe: Germany's G-BA assessed Carvykti under AMNOG in May 2025, and NICE recommended Aucatzyl for routine NHS commissioning from January 2026. (AMNOG benefit assessment (G-BA) and NICE technology appraisal)
National insurance coverage — China added JW Therapeutics' relma-cel to its first national commercial health insurance catalog for new drugs in December 2025, while Singapore's MediShield Life began paying up to S$141,000 per CAR-T treatment from June 2026. (China national commercial health insurance drug catalog (first edition, December 2025))
Public manufacturing program — Brazil's Ministry of Health funds the Carthedrall program with the Ribeirão Preto Blood Center, USP and the Butantan Institute to produce CAR-T cells domestically for the public SUS system. (Carthedrall program (Brazilian Ministry of Health))
What Recent Developments Are Shaping the CAR-T Cell Therapy Market?
Recent activity splits two ways: regulators are widening access to today's autologous products, while large pharma groups are spending billions to own the in-vivo, BCMA and solid-tumor programs that come next.
| Date | Company | Type | Description | Market Impact |
|---|---|---|---|---|
| Mar 2025 | AstraZeneca | M&A | Agreed to acquire Belgium's EsoBiotec and its ENaBL in-vivo lentiviral platform for up to USD 1.0 Bn (USD 425 Mn upfront). [source] | Brought a top-10 pharma group into in-vivo CAR-T and set a valuation benchmark for later deals. |
| Jun 2025 | U.S. Food and Drug Administration | Regulatory | Eliminated REMS programs for six autologous CD19 and BCMA CAR-T therapies, cutting the required stay near the treatment center to two weeks. [source] | Lowers barriers to community and outpatient infusion, widening the U.S. treatment network. |
| Jun 2025 | AbbVie | M&A | Announced the acquisition of Capstan Therapeutics, developer of in-vivo LNP-mRNA CD19 CAR-T candidate CPTX2309 for autoimmune disease, for up to USD 2.1 Bn. [source] | Largest in-vivo CAR-T deal to date; extends CAR-T economics into immunology. |
| Dec 2025 | Bristol Myers Squibb | Regulatory | Received FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma after two or more prior lines, the first CAR-T approved in that disease. [source] | Adds a new lymphoma indication to the broadest CD19 label on the market. |
| Apr 2026 | Gilead Sciences | M&A | Completed its acquisition of Arcellx for about USD 7.8 Bn, adding BCMA CAR-T anito-cel ahead of an FDA decision expected by 23 December 2026. [source] | Gives Kite a second growth franchise in multiple myeloma as CD19 sales decline. |
| Jun 2026 | CARsgen Therapeutics | Regulatory | China's NMPA approved satri-cel, a Claudin18.2-targeted CAR-T for advanced gastric or gastroesophageal junction cancer, the world's first solid-tumor CAR-T approval. [source] | Opens the first commercial solid-tumor CAR-T market and validates a non-hematologic target. |
Research Methodology
Overall approach
Vectomat Insights sized the CAR-T Cell Therapy market by reconciling a bottom-up patient-volume model with top-down product revenue. Treated-patient estimates by indication and country were multiplied by realized prices, then checked against reported sales of approved products such as Carvykti, Yescarta, Breyanzi and Kymriah. The base year is 2025, with 2023–2024 historical data and a 2026–2035 forecast horizon.
Primary research
Primary inputs came from discussions with cell-therapy program directors at accredited treatment centers, manufacturing and supply-chain managers at product sponsors and CDMOs, and market-access specialists working on CAR-T reimbursement in the U.S., Europe and Asia Pacific. These conversations tested assumptions on vein-to-vein time, outpatient infusion share and center capacity.
Secondary research
Secondary research drew on FDA, EMA, NMPA, PMDA and MFDS approval records; company annual reports, earnings releases and SEC filings; health technology assessments from Germany's G-BA and England's NICE; CMS payment rules; and peer-reviewed clinical publications from ASH, EHA and EULAR meetings. Pricing inputs used published U.S. wholesale acquisition costs and national reimbursement prices in Japan, South Korea, China and India.
Data validation
Segment, regional and country figures were triangulated against the VMI Data Tracker and cross-checked so that sub-segments sum to the base-year total and regional shares sum to 100%.
Table of Contents: CAR-T Cell Therapy Market Report
12 chapters · 96 tables & 72 figures. Expand a chapter to see its sub-sections.
Introduction
- Market Definition and Scope
- Report Coverage and Segmentation Framework
- Base Year, Historical Period and Forecast Horizon
- Currency, Units and Assumptions
Research Methodology
- Secondary Research
- Primary Research
- Market Size Estimation
- Data Triangulation and Validation
Executive Summary
- Key Findings
- Market Snapshot, 2025
- Analyst Viewpoint
Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- AI and Digital Manufacturing Impact
- Pricing and Reimbursement Analysis
- Regulatory Framework
CAR-T Cell Therapy Market — By Product Type
- Autologous CAR-T
- Allogeneic CAR-T
- In-Vivo CAR-T
- Production & Volume Analysis, 2025 (patients treated)
CAR-T Cell Therapy Market — By Target Antigen
- CD19-Targeted
- BCMA-Targeted
- CD22-Targeted
- Others
CAR-T Cell Therapy Market — By Application
- Non-Hodgkin Lymphoma
- Acute Lymphoblastic Leukemia
- Multiple Myeloma
- Solid Tumors
- Others
CAR-T Cell Therapy Market — By End User
- Hospitals & Cancer Centers
- Specialty Treatment Centers
- Academic & Research Institutes
Regional Analysis
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East
- Africa
Competitive Landscape
- Market Share Analysis, 2025
- Competitive Positioning Matrix
- Company Profiles
Recent Developments
- Regulatory Approvals and Label Expansions
- Mergers, Acquisitions and Licensing
- Manufacturing Capacity Investments
Appendix
- Abbreviations
- Disclaimer
- About Vectomat Insights
List of Tables (selected)
- CAR-T Cell Therapy Market Size, Global, 2023–2035 (USD Million)
- CAR-T Cell Therapy Market Size, By Product Type, 2023–2025 (USD Million)
- CAR-T Cell Therapy Market Size, By Target Antigen, 2023–2025 (USD Million)
- CAR-T Cell Therapy Market Size, By Application, 2023–2025 (USD Million)
- CAR-T Cell Therapy Market Size, By End User, 2023–2025 (USD Million)
- CAR-T Cell Therapy Market Production & Volume, By Product Type, 2025 (patients treated)
- CAR-T Cell Therapy Market Share, By Region, 2025 (%)
- North America CAR-T Cell Therapy Market Size, By Country, 2023–2035 (USD Million)
- Europe CAR-T Cell Therapy Market Size, By Country, 2023–2035 (USD Million)
- Asia Pacific CAR-T Cell Therapy Market Size, By Country, 2023–2035 (USD Million)
- Latin America CAR-T Cell Therapy Market Size, By Country, 2023–2035 (USD Million)
- The Middle East CAR-T Cell Therapy Market Size, By Country, 2023–2035 (USD Million)
- Africa CAR-T Cell Therapy Market Size, By Country, 2023–2035 (USD Million)
- Approved CAR-T Cell Therapies, By Target Antigen and Indication, 2025
- U.S. List Prices of Approved CAR-T Cell Therapies, 2025 (USD)
- Key Companies in the CAR-T Cell Therapy Market: Primary Focus and Strategy
- CAR-T Cell Therapy Market: Recent Developments, 2025–2026
- CAR-T Cell Therapy Market: Drivers, Restraints, Opportunities and Challenges Summary
List of Figures (selected)
- CAR-T Cell Therapy Market Size, USD Million, 2025–2035
- CAR-T Cell Therapy Market: Drivers, Restraints, Opportunities & Challenges
- CAR-T Cell Therapy Market Share by Region, 2025
- CAR-T Cell Therapy Market — Segmentation Overview
- CAR-T Cell Therapy Market Share, By Product Type, 2025 (%)
- CAR-T Cell Therapy Market Share, By End User, 2025 (%)
- CAR-T Cell Therapy Market — Product Type Mix by Region
- CAR-T Cell Therapy Market — Competitive Landscape
- CAR-T Cell Therapy Market — At a Glance
- United States CAR-T Cell Therapy Market Size, USD Million
- Germany CAR-T Cell Therapy Market Size, USD Million
- South Korea CAR-T Cell Therapy Market Size, USD Million
You May Also Be Interested In
NK Cell Therapy Market
Adjacent immune-cell therapy class competing for the same oncology and autoimmune buyers.
Cell Line Development Market
Upstream supplier relationship for vector production and cell-processing inputs.
Serum-Free Cell Culture Media Market
Key consumable in CAR-T expansion and manufacturing.
Healthcare Cold Chain Packaging Market
Cryopreserved CAR-T doses depend on specialized cold-chain logistics.
All VMI market research reports available in PDF. Contact sales@vectomatinsights.com
Frequently Asked Questions
What does the VMI CAR-T Cell Therapy report include?
The report covers market size from 2023 to 2025 and forecasts through 2035 across four segmentation dimensions: Product Type, Target Antigen, Application and End User. It includes six regional analyses in which Middle East and Africa are separate regions, 35+ country breakdowns, a Production & Volume analysis, drivers, restraints, opportunities and challenges, and profiles of 15 companies, in 300+ pages from Vectomat Insights.
What is the CAR-T Cell Therapy market size and forecast?
Vectomat Insights values the Global CAR-T Cell Therapy market at USD 4,372.8 Mn in 2025 and forecasts USD 23,915.3 Mn by 2035, an 18.52% CAGR across 2026–2035. Autologous products generate 68.0% of base-year revenue, while allogeneic and in-vivo platforms together hold 32.0% and carry most of the long-term upside as manufacturing models change, according to the VMI CAR-T Cell Therapy Market report.
How is the CAR-T Cell Therapy market segmented in this report?
Four dimensions are covered, each with 2023–2025 revenue tables and 2035 forecasts. Product Type splits autologous, allogeneic and in-vivo CAR-T. Target Antigen splits CD19, BCMA, CD22 and other targets such as Claudin18.2. Application covers non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma, solid tumors and others. End User covers hospitals and cancer centers, specialty treatment centers and academic and research institutes, per Vectomat Insights.
Which countries are covered in this report?
The report covers 35+ countries across six regions: North America (U.S., Canada, Mexico), Europe (including Germany, France, U.K., Italy and Spain), Asia Pacific (including China, Japan, India, South Korea and Australia), Latin America (including Brazil and Argentina), the Middle East (GCC, Israel, Turkey, Iran) and Africa (including South Africa and Egypt). Middle East and Africa are separate regions in this analysis, according to Vectomat Insights.
What customization options are available?
Buyers can request up to 20% free customization. Typical requests include extra country breakdowns, additional company profiles, splits by line of therapy or manufacturing model, and pricing and reimbursement tables for specific markets. Customization is scoped before purchase, so the delivered report matches your decision. Custom scopes beyond that allowance are quoted separately. Contact sales@vectomatinsights.com with your requirements and a Vectomat Insights analyst will confirm scope and delivery timing.
How can I access or purchase the CAR-T Cell Therapy report?
Visit www.vectomatinsights.com to request a free sample, view the table of contents or buy the full CAR-T Cell Therapy Market report. A sample shows the report's structure and data depth before you commit. Single-user, multi-user and enterprise licenses are available, with delivery as a PDF by email and through the online download portal. For corporate licensing or bulk purchases, email sales@vectomatinsights.com, and the Vectomat Insights team will respond with options.
What research methodology does VMI use for this report?
Vectomat Insights combines a bottom-up model of treated patients and realized prices with a top-down check against reported sales of approved CAR-T products. Inputs include regulatory approval records, company filings, CMS payment rules, health technology assessments from G-BA and NICE, and clinical data from major congresses. Segment and regional figures are triangulated against the VMI Data Tracker, according to Vectomat Insights.
Access the Complete CAR-T Cell Therapy Market Report
300+ pages | 96 tables & 72 figures | 2026–2035 | All 6 regions | PDF
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is a leading market research company. We create authoritative, data-forward reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organisations but also with the newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is updated constantly in order to fulfil our clients' requirements for prompt and direct online access. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com
Request a free sample
Ready to go deeper? Request a free sample of the VMI CAR-T Cell Therapy Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.